


Trial design: Patients discharged after a medical illness were randomized to rivaroxaban 10 mg daily (n = 6,007) vs. placebo (n = 6,012) for 45 days.



RESULTS

- Death from thromboembolism or symptomatic venous thromboembolism: 0.83% of the rivaroxaban group vs. 1.10% of the placebo group (p = 0.14)
- Symptomatic venous thromboembolism: 0.18% for rivaroxaban vs. 0.42% for placebo (p < 0.05)
- Major bleeding: 0.28% for rivaroxaban vs. 0.15% for placebo (p = NS)

CONCLUSIONS

- Among patients discharged after hospitalization for a medical illness, rivaroxaban was not beneficial
- Rivaroxaban failed to reduce the incidence of the primary outcome of death or recurrent thromboembolism

Spyropoulos AC, et al. N Engl J Med 2018;379:1118-27



AMERICAN
COLLEGE of
CARDIOLOGY